1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits to the Stakeholder
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Processes
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. CXO Perspective
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. HUMAN INSULIN MARKET BY PRODUCT TYPE
5.1. Introduction
5.2. Rapid-Acting Insulin
5.3. Long-Acting Insulin
5.4. Combination Insulin
5.5. Biosimilar
5.6. Others
6. HUMAN INSULIN MARKET BY APPLICATION
6.1. Introduction
6.2. Type 1 Diabetes Mellitus
6.3. Type 2 Diabetes Mellitus
7. HUMAN INSULIN MARKET BY DISTRIBUTION CHANNEL
7.1. Introduction
7.2. Hospitals
7.3. Retail Pharmacies
7.4. Others
8. HUMAN INSULIN MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Product Type
8.2.2. By Application
8.2.3. By Distribution Channel
8.2.4. By Country
8.2.4.1. USA
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. By Product Type
8.3.2. By Application
8.3.3. By Distribution Channel
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. By Product Type
8.4.2. By Application
8.4.3. By Distribution Channel
8.4.4. By Country
8.4.4.1. United Kingdom
8.4.4.2. Germany
8.4.4.3. France
8.4.4.4. Italy
8.4.4.5. Spain
8.4.4.6. Others
8.5. Middle East and Africa
8.5.1. By Product Type
8.5.2. By Application
8.5.3. By Distribution Channel
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. UAE
8.5.4.3. Others
8.6. Asia Pacific
8.6.1. By Product Type
8.6.2. By Application
8.6.3. By Distribution Channel
8.6.4. By Country
8.6.4.1. China
8.6.4.2. Japan
8.6.4.3. India
8.6.4.4. South Korea
8.6.4.5. Indonesia
8.6.4.6. Taiwan
8.6.4.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Eli Lilly and Company
10.2. Sanofi
10.3. Novo Nordisk A/S
10.4. Biocon
10.5. Boehringer Ingelheim
10.6. Tonghua Dongbao Pharmaceutical Co.
10.7. Wockhardt
10.8. Julphar
10.9. Gan & Lee Pharmaceuticals
10.10. Biocon
10.11. Bioton
10.12. Novo Nordisk Pharmatech
10.13. Sigma-Aldrich
10.14. CDH Fine Chemical
10.15. BioGems